Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "REGOMA-OS Study Analyzing Regorafenib Efficacy & Safety in Recurrent Glioblastoma Patients"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Giuseppe Lombardi
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Giuseppe Lombardi
Login to view comments.
Click here to Login
CNS